tbuckley/cabot-search huggingface dataset:
Quality of life among African-American and caucasian-American patients diagnosed with mycosis fungoides
Authors: Kai M. Bullard, Azadeh T. Stark, Andrew Kontos, David Fivenson, Henry W. Lim
Journal: Cancer Research (2004)

1405    Purpose:  Mycosis fungoides (MF) is a malignancy of mature helper T-cells that initially invades the skin with clinical manifestations of widespread erythroderma, severe pruritus, and ulcerations. We conducted a study to evaluate the change in quality of life (QoL) of individuals diagnosed with MF. Also, we evaluated the racial disparity in QoL post-diagnosis.  Experimental Design:  A retrospective cross-sectional study was designed; potential study participants were identified from the Henry Ford Health System tumor registry. Eligibility criteria included (1) confirmed pathologic diagnosis of mycosis fungoides and (2) 18 years of age or older at the time of diagnosis. QoL was measured using two self-administered instruments, each comprised of four domains: emotional, functional, physical, and social/family well-being. Income was estimated from Census data. For each instrument, a composite score of the four sub-categories made up the overall QoL score, standardized to a scale of 0 to 100. Internal consistency of the QoL domains was assessed by Cronbach coefficient alpha values. The impact of ethnicity on QoL was analyzed by Student t-tests and Wilcoxon-Mann-Whitney tests.  Results:  Of the 123 individuals who participated in this study, 27.5% were African-American (AA), and 72.5% were Caucasian American (CA). At the time of diagnosis, the mean age for AAs was 56.0 years vs. 58.9 years for CAs (p=0.355). The estimated mean annual income for AAs was significantly lower than CAs (p=0.0005). There were no statistically significant differences between AAs and CAs by age, gender, or stage at first diagnosis. However, at the time of the last treatment, 31.3% AAs vs. 16.3% CAs were classified as stage II or higher (p=0.047). Although more CAs reported a positive change and AAs reported a negative change in emotional well-being between the first diagnosis and the last treatment, the difference was not statistically significant. Both ethnic groups reported a positive change in physical and functional well-being scores, while scores for social/family well-being declined for both ethnic groups.  Conclusions:  Our preliminary analysis suggests that there was no statistically significant difference in the QoL between CAs and AAs. However, more AAs reported a decrease in QoL, while more CAs reported an overall increase in QoL between the time of the first diagnosis and the last treatment. The self-reported change in QoL may be a function of cultural values and/or progression of the disease among AA patients.
L'Internet, un outil simple et pratique pour le dépistage de Chlamydia
Authors: D Novak, A C Edman, M. Jonsson, R B Karlsson
Journal: Eurosurveillance (2003)

Cette etude vise a evaluer une nouvelle methode de depistage de C. trachomatis, reposant sur une strategie de prelevement a domicile et sur l'utilisation de l'internet comme outil pour transmettre les resultats aux participants. Une etude de depistage basee sur la population a ete organisee dans les services de soins primaires d'Umea en Suede. Y etaient inclus tous les hommes de 22 ans (n = 1074), residant a Umea, ville de 100 000 habitants. Le taux de participation etait de 38,5%. Dans le groupe etudie, 1,1% etait infecte par C. trachomatis. Le nombre de consultations internet a depasse le nombre d'echantillons urinaires testes. Les participants ont obtenu leurs resultats par internet et les trois quarts des hommes infectes ont consulte par la suite. La strategie de depistage de C. trachomatis utilisant internet a obtenu le plus fort taux de participation chez les hommes jamais publie, touchant egalement les jeunes n'appartenant pas aux groupes a risque eleve
Annals Story Slam - How Wonder Woman Became My Alter Ego
Authors: Susan Thompson Hingle
Journal: Annals of Internal Medicine (2017)

Web Exclusives7 November 2017Annals Story Slam - How Wonder Woman Became My Alter EgoFREESusan Thompson Hingle, MDSusan Thompson Hingle, MDSouthern Illinois University, Springfield, Illinois (S.T.H.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0068 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - How Wonder Woman Became My Alter Ego "How Wonder Woman Became My Alter Ego," by Dr. Susan Thompson Hingle (Duration 4:49)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video. Here, Dr. Hingle relays her story of balancing doctoring and parenting.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Southern Illinois University, Springfield, Illinois (S.T.H.)Current Author Address: Susan Thompson Hingle, MD, Southern Illinois University, 801 North Rutledge, Room 4237, Mailcode 9628, Springfield, IL 62794; e-mail, [email protected]edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 November 2017Volume 167, Issue 9Page: SS1KeywordsInterleukins ePublished: 7 November 2017 Issue Published: 7 November 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
PDCT-18. TREATMENT RESULTS OF COMBINED NEOADJUVANT CHEMOTHERAPY AND RADIOTHERAPY IN ADULT INTRACRANIAL GERM CELL TUMOR PATIENTS: A SINGLE-INSTITUTIONAL STUDY
Authors: Jae-Sung Park, Young-Joo Kim, Sin-Soo Jeun, Stephen Ahn, Yong-Kil Hong
Journal: Neuro-Oncology (2017)

Although intracranial germ cell tumors are mostly diagnosed in pediatric age group, small proportions of patients are also present in young adults. Here we report our treatment experience in adults of combined neoadjuvant chemotherapy and radiotherapy protocol, originally designed for pediatric patients by the Korean Society for Pediatric Neuro-Oncology (KSPNO). The radiation dosage was stratified by the disease extent and response to the chemotherapy. With retrospective medical chart review from 2006 to 2016, 11 adult patients were identified to be diagnosed as intracranial germ cell tumor and treated in our institution. The patient demographics, tumor location and diagnosis, treatment modality and their prognosis data were gained. All the patients were male with 1 exception, and the median age was 23 (range 20-28). Tumor locations were 4 suprasellar, 5 pineal, and 2 suprasellar, pineal combined. Radiologic evidence of leptomeningeal seeding was present in 4 cases. The diagnosis was germinoma in 8 cases, including 1 case harboring syncytiotrophoblastic giant cells. Remaining 3 cases were diagnosed as yolk sac tumor, choriocarcinoma, and mixed germ cell tumor. Nine patients underwent the aforementioned combined chemotherapy and radiotherapy protocol, and the initial response was CR in 6 patients and PR in 3 patients. Median follow up period was 59.5 months (range 12.3-113.3) and two patients expired due to disease progression at 15.3 months and 19.0 months, whom was initially diagnosed as yolk sac tumor and choriocarcinoma, respectively. No serious treatment-related complications were observed in our patient series. Despite the limited case number of our series, our treatment protocol seems safe and efficient in adult intracranial germ cell tumor patients.
Glyphosate Use and Cancer Incidence in the Agricultural Health Study
Authors: Gabriella Andreotti, Stella Koutros, Jonathan N Hofmann, Dale P Sandler, Jay H Lubin, Charles F Lynch, Catherine C Lerro, Anneclaire J De Roos, Christine G Parks, Michael C Alavanja, Debra T Silverman, Laura E Beane Freeman
Journal: JNCI Journal of the National Cancer Institute (2017)

Glyphosate is the most commonly used herbicide worldwide, with both residential and agricultural uses. In 2015, the International Agency for Research on Cancer classified glyphosate as "probably carcinogenic to humans," noting strong mechanistic evidence and positive associations for non-Hodgkin lymphoma (NHL) in some epidemiologic studies. A previous evaluation in the Agricultural Health Study (AHS) with follow-up through 2001 found no statistically significant associations with glyphosate use and cancer at any site.
P1.07-022 Routine PD-L1 Immunohistochemistry Testing by 22C3 in a Canadian Reference Testing Center
Authors: T. Albaqer, R. Santiago, Y. Leung, P. Pal, Z. Khan, E. Torlakovic, C. Cheung, D. Hwang, M. Tsao
Journal: Journal of Thoracic Oncology (2017)
Breast Mass in a Man
Authors: Ali Jad Yousef
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Respuesta a las cartas : Brotes de parvovirus B19
Authors: G Gonçalves, A M Correia, P Palminha, Helena Rebelo-Andrade, A Alves
Journal: Eurosurveillance (2005)

We are grateful for the comments provided by Kelly and Leydon, and Bernard J Cohen. They seem to share our previously expressed opinion that ’in the context of measles and rubella elimination programs, study protocols should include data collection procedures and laboratory tests able to confirm or discard the diagnosis of B19 infections.’ [1]. They have provided a useful commentary with relevant information and references.
Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial
Authors: Channing J. Paller, Xian C. Zhou, Elisabeth I. Heath, Mary-Ellen Taplin, Tina Mayer, Mark N. Stein, Glenn J. Bubley, Roberto Pili, Tamaro Hudson, Radhika Kakarla, Muneer M. Abbas, Nicole M. Anders, Donna Dowling, Serina King, Ashley B. Bruns, William D. Wagner, Charles G. Drake, Emmanuel S. Antonarakis, Mario A. Eisenberger, Samuel R. Denmeade, Michelle A. Rudek, Gary L. Rosner, Michael A. Carducci
Journal: Clinical Cancer Research (2017)

Abstract Purpose: MuscadinePlus (MPX), a commercial preparation of pulverized muscadine grape skin, was evaluated as a therapeutic option for men with biochemically recurrent (BCR) prostate cancer wishing to defer androgen deprivation therapy. Experimental Design: This was a 12-month, multicenter, placebo-controlled, two-dose, double-blinded trial of MPX in 125 men with BCR prostate cancer, powered to detect a PSA doubling time (PSADT) difference of 6 months (low dose) and 12 months (high dose) relative to placebo. Participants were stratified (baseline PSADT, Gleason score) and randomly assigned 1:2:2 to receive placebo, 500 mg MPX (low), or 4,000 mg MPX (high) daily. Correlates included superoxide dismutase-2 (SOD2) genotype, lipid peroxidation, and polyphenol pharmacokinetics. Results: The evaluable population included 112 patients, all treated for at least 6 months and 62% treated for 12 months. No significant difference was found in PSADT change between control and treatment arms (P = 0.81): control 0.9 months (n = 20; range, 6.7–83.1), low dose 1.5 months (n = 52; range, 10.3–87.2), high dose 0.9 months (n = 40; range, 27.3–88.1). One high-dose patient experienced objective response. No drug-related CTCAE grade 3–4 adverse events were seen. In a preplanned exploratory analysis, PSADT pre-to-post increase was significant in the 27 (26%) genotyped patients with SOD2 Alanine/Alanine genotype (rs4880 T&amp;gt;C polymorphism) on MPX (pooled treatment arms; 6.4 months, P = 0.02), but not in control (1.8 months, P = 0.25). Conclusions: Compared with placebo, MPX did not significantly prolong PSADT in BCR patients over two different doses. Exploratory analysis revealed a patient population with potential benefit that would require further study. Clin Cancer Res; 24(2); 306–15. ©2017 AACR.
P3.03-012 The Relationship between Efficacy of Wee1 Inhibitor AZD1775 and Mutational Status of TP53 in KRAS-Mutant Non-Small Cell Lung Cancer
Authors: B.M. Ku, Y. Bae, J. Koh, J. Sun, S. Lee, J.S. Ahn, K. Park, M. Ahn
Journal: Journal of Thoracic Oncology (2017)
NCMP-09. ANTICONVULSANT PROPHYLAXIS IN PATIENTS WITH BRAIN TUMORS: DOES IT PREVENT FIRST SEIZURES, DOES IT PROLONG SURVIVAL, AND DO WE BELIEVE THE DATA?
Authors: Ayesha Ali, Christina Zoccoli, Lyndon Kim, Timothy Brown, Michael Glantz
Journal: Neuro-Oncology (2017)

Despite an American Academy of Neurology Practice Guideline, a Cochrane Review, and multiple meta-analyses suggesting that anticonvulsant prophylaxis in patients with primary and metastatic brain tumors is ineffective, widespread practice variation and unanswered questions persist. Exhaustive evidence-based literature searches were conducted, and additional patient-level data from randomized controlled trials were analyzed to answer three questions: does anticonvulsant prophylaxis reduce the risk of first seizures in patients with primary and metastatic brain tumors (5 RCTs); does valproic acid improve survival in patients with primary and metastatic brain tumors (6 trials); and what effect have practice guidelines had on physician attitudes and actual practice with regard to anticonvulsant prophylaxis (8 studies). Anticonvulsant prophylaxis did not reduce the risk of a first seizure (OR= 0.95 [0.58-1.55], p= 0.85, anticonvulsant prophylaxis vs. no prophylaxis, random effects model). For brain metastasis patients only the OR was 0.96 [0.73-1.25], p=0.77. For primary brain tumor patients only the OR was 1.03 [0.19-5.72], p=0.97. Physician-reported practice of prescribing anticonvulsant prophylaxis (pre- vs. post-guideline publication) decreased (55% vs. 31%, mean decrease 23.7% [22.6-24.9], p<0.001, Cohen’s d=2.75). Actual anticonvulsant use also decreased (77% vs. 47%, mean decrease 25.5% [25.1-25.9%], p<0.001, Cohen’s d=4.61). Patients receiving valproic acid had a lower risk of death compared to those who did not receive valproic acid (HR 0.84 [0.72-0.98], p=0.027). Anticonvulsant prophylaxis has not been demonstrated to reduce the risk of first seizures in patients with primary or metastatic brain tumors. Despite this well-publicized evidence, a substantial number of physicians favor and continue to prescribe anticonvulsant prophylaxis. Patients receiving valproic acid experience a lower risk of death compared with those who do not receive valproic acid. Further research regarding the use of anticonvulsants within specific tumor sub-populations, and regarding the failure of practice guidelines to change physician practice are warranted.
Acute Kidney Injury
Authors: Andrew S. Levey, Matthew T. James
Journal: Annals of Internal Medicine (2017)

This article has been corrected. The original version (PDF) is appended to this article as a Supplement. Acute kidney injury is a heterogeneous group of conditions characterized by a sudden decrease in glomerular filtration rate, manifested by an increase in serum creatinine concentration or oliguria, and classified by stage and cause. This type of injury occurs in approximately 20% of hospitalized patients, with major complications including volume overload, electrolyte disorders, uremic complications, and drug toxicity. Management includes specific treatments according to the underlying cause and supportive treatment to prevent and manage complications. Kidney replacement therapy is used when complications cannot be managed with medical therapy alone. Despite advances in care, the mortality rate in patients requiring kidney replacement therapy remains approximately 50%.
SCDT-21. CEREBRAL INTRAARTERIAL CHEMOTHERAPY IN THE TREATMENT OF MALIGNANT GLIOMAS: READY TO RISE AGAIN
Authors: David Fortin, Gerald Gahide, Celine D’aout, Isabelle St-Pierre, Marie-André Roy, Christian Iorio-Morin
Journal: Neuro-Oncology (2017)

Contemporary treatment of glioblastoma involves an optimal surgery, followed by a combination of radiation and temozolomide. The reported progression-free survival with this treatment is only 6.9 months. At recurrence, few therapeutic options are available given the paucity of chemotherapeutics crossing the blood-brain barrier (BBB). Cerebral Intra-arterial Chemotherapy (CIAC) in the treatment of gliomas allows to bypass the BBB and the brain-tumor barrier (BTB), but fell into oblivion after a major randomized study led by the BTCG showed no therapeutic advantages, and a major complication profile. Looking at the reasons for this failure, the choice of chemotherapeutics, concentration, volume and infusion rate, catheter placement can all be invoked. But nowadays, with refinements in angiographic hardware and technics, and the availability of new therapeutics, CIAC is ready to rise again. In this work, we present the largest series of glial tumors treated by CIAC to our knowledge. Over 15 years, 463 glial tumors comprising 319 GBM tumors were treated at the CHUS (centre Hospitalier Universitaire de Sherbrooke) with a standardized CIAC protocol of monthly carboplatin administration. All patients were treated at relapse. Seventeen percent were treated at first relapse, 68% at second relapse, 11% at third relapse and 4% at fourth. Overall, the patient received a median of 4 cycles (1 to 22 cycles). The whole series presented an overall median survival of 25 months, whereas survival from study entry was 8 months for the entire cohort. Ten patients are still alive, with the longest survival now at 12 years. The overall complication rate was 0.75%, with the most frequent occurrence being lacunar strokes. We believe that a better selection of patient, molecular subclassification, and the continued search for chemotherapeutics will improve these results. The procedure is safe, and should be considered an easy and viable delivery option to circumvent BBB.
Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial
Authors: Andreas Kronenberg, Lukas Bütikofer, Ayodele Odutayo, Kathrin Mühlemann, Bruno R da Costa, Markus Battaglia, Damian N Meli, Peter Frey, Andreas Limacher, Stephan Reichenbach, Peter Jüni
Journal: BMJ (2017)

<b>Objective</b>&nbsp;To investigate whether symptomatic treatment with non-steroidal anti-inflammatory drugs (NSAIDs) is non-inferior to antibiotics in the treatment of uncomplicated lower urinary tract infection (UTI) in women, thus offering an opportunity to reduce antibiotic use in ambulatory care. <b>Design</b>&nbsp;Randomised, double blind, non-inferiority trial. <b>Setting</b>&nbsp;17 general practices in Switzerland. <b>Participants</b>&nbsp;253 women with uncomplicated lower UTI were randomly assigned 1:1 to symptomatic treatment with the NSAID diclofenac (n=133) or antibiotic treatment with norfloxacin (n=120). The randomisation sequence was computer generated, stratified by practice, blocked, and concealed using sealed, sequentially numbered drug containers. <b>Main outcome measures</b>&nbsp;The primary outcome was resolution of symptoms at day 3 (72 hours after randomisation and 12 hours after intake of the last study drug). The prespecified principal secondary outcome was the use of any antibiotic (including norfloxacin and fosfomycin as trial drugs) up to day 30. Analysis was by intention to treat. <b>Results</b>&nbsp;72/133 (54%) women assigned to diclofenac and 96/120 (80%) assigned to norfloxacin experienced symptom resolution at day 3 (risk difference 27%, 95% confidence interval 15% to 38%, P=0.98 for non-inferiority, P&lt;0.001 for superiority). The median time until resolution of symptoms was four days in the diclofenac group and two days in the norfloxacin group. A total of 82 (62%) women in the diclofenac group and 118 (98%) in the norfloxacin group used antibiotics up to day 30 (risk difference 37%, 28% to 46%, P&lt;0.001 for superiority). Six women in the diclofenac group (5%) but none in the norfloxacin group received a clinical diagnosis of pyelonephritis (P=0.03). <b>Conclusion</b>&nbsp;Diclofenac is inferior to norfloxacin for symptom relief of UTI and is likely to be associated with an increased risk of pyelonephritis, even though it reduces antibiotic use in women with uncomplicated lower UTI. <b>Trial registration</b>&nbsp;ClinicalTrials.gov NCT01039545.
P3.01-053 Detection of Common EGFR Mutation in Cytological Smears Using Reversed Dot Blot (RDB) Hybridization Method
Authors: N. Masykura, D. Kwang, J. Zaini, S. Andarini, A. Hudoyo, E. Syahruddin, M. Levi, G. Widjajahakim, A. Utomo
Journal: Journal of Thoracic Oncology (2017)
P1.07-044 The Impact of Neutrophil/Lymphocyte Ratio as the Predictive Marker to Anti-PD-1 Antibody Treatment in NSCLC Patients
Authors: K. Tanimura, T. Yamada, N. Tamiya, Y. Kaneko, J. Uchino, K. Takayama
Journal: Journal of Thoracic Oncology (2017)
P2.02-030 Bavituximab in Combination With Nivolumab Enhances Tumor Immune Response in a 3D Ex Vivo System of Lung Cancer Patients
Authors: M. Mediavilla-Varela, M.M. Page, J. Kreahling, B. Freimark, J. Shan, N. Kallinteris, S. Antonia, S. Altiok
Journal: Journal of Thoracic Oncology (2017)
NIMG-67. ADVANCED PERFUSION AND DIFFUSION MR IMAGING IN GLIOBLASTOMA PATIENTS TREATED WITH TUMOR TREATING FIELDS (TTFIELDS) AS FIRST-LINE THERAPY
Authors: Jennifer M Connelly, Melissa A Prah, Kathleen M Schmainda
Journal: Neuro-Oncology (2017)

Tumor treating fields (TTFields) is an antimitotic and FDA-approved first and second-line therapy for patients with glioblastoma. In recurrent glioblastoma, it has been reported that imaging response to TTFields is generally delayed (~158 days), where 44% of responders developed initial tumor growth on standard imaging. However, there are currently no published reports containing a systematic review of imaging with regards to response in patients treated with TTFields as a first-line therapy. The aim of this preliminary analysis is to examine the potential of advanced imaging as an early response indicator. Advanced MRI was evaluated in 8 patients with newly diagnosed glioblastoma after completing concomitant chemoradiotherapy followed by adjuvant temozolomide in combination with TTFields. When available, FLAIR volume (FV) and enhancing tumor volumes (ETV) were examined with diffusion (ADC) and DSC-perfusion (standardized rCBV, normalized CBF) within 90 days following initiation of TTFields. In addition fractional tumor burden (FTB), a recently described DSC-perfusion biomarker, was compared. Although not significant and likely due to the smaller sample size, standardized rCBV, FTB, and ADC had a nearly 2-fold or better correlation with progression free survival (r = -0.56, -0.63, 0.76) than ETV, FV and CBF (r = -0.34, -0.31, -0.38). The results of this study show that while standard morphologic imaging does not correlate with response to upfront TTF therapy, during the first 90 days, advanced imaging has the potential to identify responders earlier. Further analysis in a larger, prospective cohort is underway, where future goals include determining the optimal imaging time frame that best predicts response to treatment and improved survival.